Part 1/8:
The Impact of Tariffs and Policy Changes on U.S. Pharma-Biotech Sector
In recent market movements, pharmaceutical and biopharmaceutical companies experienced a modest decline of about 1.5%, reflecting broader concerns over trade policies and tariffs. Experts are closely analyzing how these companies can mitigate the potential adverse effects of trade barriers, especially with the evolving policy landscape.